Hostname: page-component-8448b6f56d-c47g7 Total loading time: 0 Render date: 2024-04-24T07:23:45.987Z Has data issue: false hasContentIssue false

Effects of Ethyl Ester Derivatives of Valproic Acid Metabolites on Pentylenetetrazol Seizures in Mice

Published online by Cambridge University Press:  18 September 2015

J. Bruni*
Affiliation:
Department of Neurology, University of Florida, College of Medicine, Gainesville, Florida, U.S.A.
E.J. Hammond
Affiliation:
Department of Neurology, University of Florida, College of Medicine, Gainesville, Florida, U.S.A.
B.J. Wilder
Affiliation:
Department of Neurology, University of Florida, College of Medicine, Gainesville, Florida, U.S.A.
*
Suite 318, E.K. Jones Building, Wellesley Hospital, 160 Wellesley St. East. Toronto, Ontario, Canada, M4Y 1J3. (416) 966-6723
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The anticonvulsant activity of the ethyl esters of the major valproic acid metabolites was assessed against minimal pentylenetetrazol seizures in adult male ICR mice. The ethyl ester 3-hydroxy-propylpentanoic acid was found to possess significant anticonvulsant activity.

Type
Research Article
Copyright
Copyright © Canadian Neurological Sciences Federation 1981

References

REFERENCES

Bruni, J., Wilder, B.J. (1979). Valproic acid: Review of a new anti-epileptic drug. Arch. Neurol. 36, 393398.CrossRefGoogle Scholar
Bruni, J., Wilder, B.J., Bauman, A.W., Willmore, L.J. (1980). Clinical and long-term effects of valproic acid therapy on spike-and-wave discharges. Neurology, 30, 4246.Google Scholar
Ferrandes, B., Eymard, P. (1977). Metabolism of valproate sodium in rabbit, rat, dog, and man. Epilepsia, 18, 169182.CrossRefGoogle ScholarPubMed
Goldberg, M.A., Todoroff, T. (1980). Brain binding of anticonvulsants: Carbamazepine and valproic acid. Neurology, 30, 826831.CrossRefGoogle ScholarPubMed
Gompertz, D., Tippett, P., Bartlett, K., Baillie, T. (1977). Identification of urinary metabolites of sodium dipropylacetate in man. Potential sources of interference in organic acid screening procedures. Clin. Chim. Acta, 74, 153160.CrossRefGoogle ScholarPubMed
Gugler, R., Schnell, A., Eichelmaum, M., Froscher, W., Schulz, H.U. (1977). Disposition of valproic acid in man. Eur. J. Clin. Pharmacol. 12, 125132.Google ScholarPubMed
Jakobs, C, Loscher, W. (1978). Identification of metabolites of valproic acid in serum of humans, dogs, rat, and mouse. Epilepsia, 19, 591602.CrossRefGoogle ScholarPubMed
Kuhara, T., Matsumoto, I. (1974). Metabolism of branched medium chain length fatty acids. I. ω-oxidation of sodium dipropylacetate in rats. Biomed. Mass. Spectrom. 1, 291294.CrossRefGoogle ScholarPubMed
Matsumoto, I., Kuhara, T., Yoshino, M. (1976). Metabolism of branched medium chain length fatty acid. II. /3 – oxidation of sodium dipropylacetate in rats. Biomed. Mas. Spectrom 3, 235240.CrossRefGoogle ScholarPubMed
Meunier, G., Carraz, G., Meunier, Y., Eymard, M. (1963). Properties pharmacodynamiques de l’acide n-dipropylacetique. Therapie, 18, 435438.Google Scholar
Pinder, R.M., Brogden, R.N., Speight, T.M., Avery, G.S. (1977). Sodium valproate: A review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs, 13, 81123.CrossRefGoogle ScholarPubMed
Schafer, H., Luhrs, R.Reith, H. (1980). Chemistry, pharmacokinetics, and biological activity of some metabolites of valproic acid. Pages 103110 in Johannessen, S.I., Morselli, R.L., Pippenger, C.E., Richens, A., Schmidt, D., Meinardi, H., Eds.. Antiepileptic Therapy: Advances in Drug Monitoring. Raven Press, New York.Google Scholar
Swinyard, E.A. (1969). Laboratory evaluation of antiepileptic drugs. Review of laboratory methods. Epilepsia, 10, 107119.Google ScholarPubMed
Swinyard, E.A. (1972). Assay of antiepileptic drug activity in experimental animals: Standard tests. Pages 4765 in Mercier, J., Ed., Anticonvulsant Drugs, International Encyclopedia of Pharmacology and Therapeutics, Section 19, Volume 1. Pergamon Press, Oxford/New York.Google Scholar